CD8A and infection: Given our finding that IFN-λ is critical for supporting activation of respiratory virus–specific CD8 T cell immunity (22), it is possible that administration of IFN-λ as a therapeutic during infection, or as a vaccine adjuvant, may bolster this aspect of cell-mediated immunity against SARS-CoV-2.